Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-16. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
ligand An ion, functional group, or other molecule that binds to a central metal atom to form a coordination complex. Such bonding can range from covalent to ionic, but generally involves formal donation of one or more of the ligand's electron pairs to the metal.
All dinosaurs laid amniotic eggs. Dinosaur eggs were usually laid in a nest. Most species create somewhat elaborate nests which can be cups, domes, plates, beds scrapes, mounds, or burrows. Some species of modern bird have no nests; the cliff-nesting common guillemot lays its eggs on bare rock, and male emperor penguins keep eggs between their body and feet. Primitive birds and many non-avialan dinosaurs often lay eggs in communal nests, with males primarily incubating the eggs. While modern birds have only one functional oviduct and lay one egg at a time, more primitive birds and other dinosaurs had two oviducts, like crocodiles. Some non-avialan dinosaurs, such as Troodon, exhibited iterative laying, where the adult might lay a pair of eggs every one or two days, and then ensured simultaneous hatching by delaying brooding until all eggs were laid. When laying eggs, females grow a special type of bone between the hard outer bone and the marrow of their limbs. This medullary bone, which is rich in calcium, is used to make eggshells. A discovery of features in a Tyrannosaurus skeleton provided evidence of medullary bone in extinct dinosaurs and, for the first time, allowed paleontologists to establish the sex of a fossil dinosaur specimen. Further research has found medullary bone in the carnosaur Allosaurus and the ornithopod Tenontosaurus.
Later, during the 1990s, Heseltine committed a minor gaffe when he joked in a speech about how he had strung creditors along. Between 1960 and 1964, Heseltine also worked as a part-time interviewer for ITV, very likely, in Crick's view, to maintain his public profile as an aspiring politician.
Hepatalin is a hormone produced by the liver after feeding and plays a central role in the partitioning of the storage of nutrient energy by its action on glucose uptake and formation of glycogen in muscle. Hepatalin accounts for the majority of postprandial glucose uptake. Hepatalin secretion from the liver is regulated by three signals: a hepatic parasympathetic-mediated signal, elevated hepatic glutathione (GSH), and pulses of insulin.
==== Voice acting ==== Shawn is a voice actor for animated films and television series, including the Toy Story franchise, Monsters, Inc. (during the outtakes in the closing credits), Kingdom Hearts III, The Incredibles, A Goofy Movie, Family Guy, Happily N'Ever After, Tom and Jerry: Shiver Me Whiskers, Regular Show, BoJack Horseman and Animal Crackers. Shawn said that Toy Story director John Lasseter might have seen both My Dinner with Andre and The Princess Bride and seen him as "excitable" like Shawn's character, Rex. During production of The Fox and the Hound, Shawn was originally cast as Boomer, but dropped out and was replaced by Paul Winchell. In Cats & Dogs: The Revenge of Kitty Galore, he replaced Jon Lovitz as the voice of Calico. He also voiced Mr. Mustela in The Addams Family 2.
Sources: en.wikipedia.org
Episode Two opens with Alyx and Gordon learning a superportal to the Combine dimension has formed in the Citadel's place, progressing to a stage where the Combine can send reinforcements. They also discover that Alyx's encrypted data from the Citadel can reverse the portal, and so traverse the countryside to deliver the packet to another resistance headquarters at White Forest. As they progress, Combine Advisors have escaped the Citadel's destruction, and remaining Combine forces are regrouping, albeit under attacks by Vortigaunts. Aware of the resistance's plans to close the superportal, the Combine attack White Forest in force, but are repelled. The Combine are again the primary antagonist in the prequel Half-Life: Alyx, taking place between Half-Life and Half-Life 2. The game focuses on the efforts of Alyx Vance, her father Eli, and fellow resistance member Russell, as they attempt to infiltrate a massive Combine vault, believing it possesses a weapon that they could use to weaken the Combine occupation on Earth. After navigating through various quarantine zones of City 17 and rescuing Eli, they discover that the Vault is constructed not to hold a weapon, but as a prison, which they deduce to be holding Gordon Freeman. Alyx infiltrates the Vault and learns that it does not imprison Freeman, but is instead harboring the mysterious G-Man, who shows Alyx a glimpse of Eli's death in the future and offers her a chance to prevent it, which she accepts, before placing her in stasis.
=== Conservation of mass in mixing calculations === 2H and 1H are stable isotopes. Therefore, the 2H/1H ratio of a pool containing hydrogen, remains constant as long as no hydrogen is added or removed, a property known as conservation of mass. When two pools of hydrogen A and B mix with molar amounts of hydrogen mA and mB, each with their own starting fractional abundance of deuterium (FA and FB), then the fractional abundance of the resulting mixture is given by the following exact equation:
It was thus becoming increasingly evident that the alternative of "democratic rupture" accompanied by "decisive national action" was not viable, so its main supporter, the Communist Party of Spain, decided in March 1976 to change strategy and adopt the alternative of "agreed democratic rupture" advocated by the moderate opposition and the PSOE ─ which had formed the Democratic Convergence Platform ─ although without abandoning the mobilization of citizens to exert continuous pressure on the government and force it to negotiate with the opposition. The change of strategy of the PCE, allowed the merger on March 26 of the two unitary organizations of the opposition, the Junta Democrática and the Plataforma de Convergencia Democrática, which led to the creation of Coordinación Democrática ─ popularly known as Platajunta. In its first manifesto, it rejected the "Arias-Fraga reform" and demanded an immediate political amnesty, full trade union freedom and a "rupture or democratic alternative through the opening of a constituent period". Thus, from the first scenario of rupture with popular uprising, the demand for the calling of general elections from which a constituent process could be derived. Shortly after the Platajunta was formed the government tolerated the socialist trade union Unión General de Trabajadores (UGT) to hold inside the country its XXX Congress camouflaged under the term Jornadas de Estudio (Study Days), but at the same time the police arrested the leader of CC OO, Marcelino Camacho.
==== Stimuli-responsive nanogels for drug delivery ==== Nanogels that respond to various stimuli including changes in pH and temperature or the presence of redox and light cues have proven to be useful tools for drug delivery. One such responsive nanogel was designed to switch from a surface negative charge to a surface positive charge upon exposure to decrease in pH once inside a tumor. When loaded with a chemotherapeutic agent, this technology induced a lower viability in 3D tumor spheroids compared to control groups. Another type of nanogel loaded with osteoarthritis anti-inflammatory drugs was found to significantly increase the amount of drug transported after topical application to the skin and exposure to its natural elevated temperature. One group reported a method to control the release rate of an antiplatelet medication from a nanogel by using UV light to alter the crosslinking density of the polymer and subsequently change the swelling rate. Additionally, other nanogels have been synthesized to include disulfide cleavable polymers that respond to reductive cues in the surrounding environment. One such nanogel was loaded with a chemotherapeutic agent and demonstrated a decrease in cell viability compared to a free version of the same agent.
=== Controversy and plasticity === In spite of a burgeoning literature supporting TPCs as the NAADP-regulated channel, this was challenged in 2012/13 by reports that TPCs are, instead, Na+ channels regulated by the endo-lysosomal lipid, Phosphatidylinositol 3,5-bisphosphate, PI(3,5)P2 and also by metabolic state (via ATP and mTOR). This controversy ultimately evolved into a new model of how TPCs work. The challenge raised two different, but interrelated issues: (a) TPCs are insensitive to NAADP; (b) TPCs are Na+- (and not Ca2+-) permeable.
Sources: en.wikipedia.org
This poses a real challenge for the translators because they have to render the meaning, i.e. find an equivalent, of a very specific, scientific term in the target language and frequently the narrator uses a more general name instead of a specific term and the translator has to rely on the image presented in the programme to understand which term is being discussed in order to transpose it in the target language accordingly. Additionally, translators of minorised languages often face another problem: some terms may not exist in the target language. In such cases, they have to create new terminology or consult specialists to find proper solutions. Also, sometimes the official nomenclature differs from the terminology used by actual specialists, which leaves the translator to decide between using the official vocabulary that can be found in the dictionary, or rather opting for spontaneous expressions used by real experts in real-life situations.
=== Niche uses === The polymer is also used to make Gro-Beast toys, which expand when placed in water, such as the Test Tube Aliens. Similarly, the absorbent properties of one of its copolymers can be utilized as an additive in body-powder. It has been used as a subdermal filler for aesthetic facial surgery It was also used in the synthesis of the first Boger fluid.
=== Animal fats === Trans fatty acids (TFAs) occur in small amounts in meat and milk of ruminants (such as cattle and sheep), typically 2–5% of total fat. Natural TFAs, which include conjugated linoleic acid (CLA) and vaccenic acid, originate in the rumen of these animals. CLA has two double bonds, one in the cis configuration and one in trans, which makes it simultaneously a cis- and a trans-fatty acid. A type of trans fat occurs naturally in the milk and body fat of ruminants (such as cattle and sheep) at a level of 2–5% of total fat. The US National Dairy Council has asserted that the trans fats present in foods of animal origin are of a different type than those in partially hydrogenated oils, and do not appear to exhibit the same negative effects. A scientific review agrees with the conclusion (stating that "the sum of the current evidence suggests that the Public health implications of consuming trans fats from ruminant products are relatively limited") but cautions that this may be due to the low consumption of trans fats from animal sources compared to artificial ones. Despite this concern, the NAS dietary recommendations have not included eliminating trans fat from the diet. This is because trans fat is naturally present in many animal foods in trace quantities, and thus its removal from ordinary diets might introduce undesirable side effects and nutritional imbalances if proper nutritional planning is not undertaken. The NAS has, thus, "recommended that trans fatty acid consumption be as low as possible while consuming a nutritionally adequate diet".
Protein structural modeling can be performed by examining how well the amino acid substitutions fit into the core of the three-dimensional structure. Family (structural context) as used in the FSSP database (Families of structurally similar proteins) and the DALI/FSSP Web site, two structures that have a significant level of structural similarity but not necessarily significant sequence similarity. Fold similar to structural motif, includes a larger combination of secondary structural units in the same configuration. Thus, proteins sharing the same fold have the same combination of secondary structures that are connected by similar loops. An example is the Rossman fold comprising several alternating α helices and parallel β strands. In the SCOP, CATH, and FSSP databases, the known protein structures have been classified into hierarchical levels of structural complexity with the fold as a basic level of classification. Homologous domain (sequence context) an extended sequence pattern, generally found by sequence alignment methods, that indicates a common evolutionary origin among the aligned sequences. A homology domain is generally longer than motifs. The domain may include all of a given protein sequence or only a portion of the sequence. Some domains are complex and made up of several smaller homology domains that became joined to form a larger one during evolution. A domain that covers an entire sequence is called the homeomorphic domain by PIR (Protein Information Resource).
During the development of the NA-73X, a wind-tunnel test of two wings, one using NACA five-digit airfoils and the other using the new NAA/NACA 45–100 airfoils, was performed in the University of Washington Kirsten Wind Tunnel. The results of this test showed the superiority of the wing designed with the NAA/NACA 45–100 airfoils.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.